Cancer Drug Resistance (CDR) is a high-impact, international, open-access oncology journal uniquely dedicated to cancer drug resistance research. Positioned as the definitive global voice and a translational accelerator in this field, CDR integrates fundamental mechanisms, clinical translation, and innovative therapeutic strategies to overcome resistance and improve patient outcomes. With an Impact Factor of 5.2, CDR ranks in the top 20% (Q1) of JCR oncology journals, reflecting its rigorous peer review and academic excellence. Its open-access model and globally diverse editorial board and readership ensure maximal visibility, influence, and citation worldwide.